Alzheimer’s Disease Diagnosis: Understanding the Journey to Answers

11 Feb 2026 · 4 min

Watch on YouTube

3:35

In this presentation, Lisa Skinner of Minding Dementia outlines modern approaches to diagnosing Alzheimer’s disease, emphasizing that while definitive diagnosis still requires post‑mortem brain examination, specialized centers can achieve up to 90 % clinical accuracy using a combination of biomarkers, imaging, and clinical assessments. She walks through the core diagnostic workflow—medical history, neurological exam, neuropsychological testing, blood work, and brain imaging—explaining how each component helps rule out other conditions. The talk details expert diagnostic criteria (gradual cognitive decline, objective deficits, exclusion of alternatives, clean imaging) and highlights the pivotal role of biomarkers, including CSF markers, advanced blood tests, and genetic testing. Brain imaging technologies (CT, MRI, PET) are described for their ability to reveal structural and functional changes. Genetic forms of Alzheimer’s are distinguished as familial (rare, high penetrance) versus sporadic (common, non‑hereditary). A major focus is the FDA‑approved Lumipulse blood test, which measures tau and amyloid with >90 % detection accuracy, offering a less invasive, cost‑effective option. The presentation concludes with practical next steps for patients—discussing symptoms with physicians, asking targeted questions, undergoing comprehensive evaluation, and planning treatment and lifestyle changes. Viewers are directed to the Minding Dementia website, podcast, and TV show for further resources.

Chapters

Diagnosing Alzheimer's disease involves advanced tools achieving up to 90% accuracy in specialized centers. This slide highlights the importance of precise diagnostic methods to ensure effective treatment and management of the disease. The diagnostic challenge outlines the complexities in diagnosing Alzheimer's. Definitive diagnosis is only possible postmortem through brain tissue examination. However, specialized centers can achieve 90% clinical accuracy using a combination of biomarkers, imaging, and clinical evaluations, showcasing a modern approach to diagnosis. Core diagnostic methods include a comprehensive review of medical history and neurological exams, neuropsychological testing, blood tests, and brain scans. These methods help exclude other conditions and provide a thorough assessment of cognitive health. Crucial for accurate Alzheimer's diagnosis. Expert diagnostic criteria focus on gradual cognitive decline, objective evidence of deficits, ruling out alternatives, and clean imaging. These criteria, as outlined by Dr. Barry Rovner, are essential for distinguishing Alzheimer's from other neurological conditions, ensuring precise diagnosis and treatment. Understanding biomarkers is vital in Alzheimer's diagnosis. While no single test can diagnose dementia, biomarkers are integral to a comprehensive assessment. This slide emphasizes the role of biomarkers in conjunction with other diagnostic tools to provide a complete picture of the patient's condition. Brain imaging technologies such as CT scans, MRI, and PET scans are crucial in diagnosing Alzheimer's. These technologies provide detailed images of the brain, helping to identify abnormalities and assess brain function, which are essential for accurate diagnosis and treatment planning. Additional diagnostic tests include CSF biomarkers, advanced blood tests, and genetic testing. These tests enhance diagnostic accuracy by measuring specific proteins and genetic risk factors, providing a deeper understanding of the disease's progression and potential treatment pathways. Genetic forms of Alzheimer's are categorized into familial and sporadic types. Familial Alzheimer's is a rare genetic form affecting up to half of family members, while sporadic Alzheimer's is the most common, occurring randomly without a clear genetic pattern. Understanding these forms aids in targeted diagnosis and treatment. The FDA-approved blood test, Lumipulse, offers a breakthrough in Alzheimer's diagnosis with over 90% detection accuracy. It measures tau protein and amyloid plaques, providing a less invasive and cost-effective alternative to traditional methods, with quick results for early intervention. Moving forward with diagnosis involves discussing symptoms with your doctor, asking key questions, and undergoing a comprehensive evaluation. Planning next steps, including treatment options and lifestyle changes, is crucial. Modern diagnostic tools provide strong evidence for probable diagnosis, guiding treatment and research. Brought to you by Lisa Skinner with Minding Dementia. Please visit the website for more information and links to the podcast and TV show.